New Weight-Loss drug brenipatide enters early human testing

NCT ID NCT07476118

Ongoing Disease control Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 17, 2026 · Updated 4 times

Summary

This early-stage trial is testing a new drug called brenipatide in 150 healthy people with overweight or obesity. Participants receive different doses of the drug or a placebo as injections under the skin. The study lasts about 42 weeks and aims to see how well the drug works for weight loss and how safe it is.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: brenipatide
What this could lead to: If successful, this could point toward a new weight-loss treatment for people with overweight or obesity.
What could go wrong: This is an early Phase 1 trial with only 150 participants, so results may not apply to everyone. The drug may cause side effects or fail to show meaningful weight loss.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY OVERWEIGHT

Contacts and locations

Locations

Fortrea Clinical Research Unit

Dallas, Texas, 75247, United States
Fortrea Clinical Research Unit - Daytona Beach

Daytona Beach, Florida, 32117-5116, United States
Fortrea Clinical Research Unit Inc. - Madison

Madison, Wisconsin, 53704, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.